Key result
Stent postdilation during primary percutaneous coronary intervention for STEMI was associated with a decreased risk of the device-oriented composite endpoint.
Why the study?
Achieving optimal coronary stent apposition during PCI is not always feasible, and the risks and benefits of stent postdilation during PPCI for STEMI have remained controversial.
Does stent postdilation improve angiographic and clinical outcomes in patients with STEMI undergoing primary percutaneous coronary intervention?
Cohort (n=1,224)
Does stent postdilation improve angiographic and clinical outcomes in patients with STEMI undergoing primary percutaneous coronary intervention?
Selective stent postdilation during primary PCI for STEMI is associated with improved long-term device-oriented clinical outcomes without compromising immediate angiographic results.
Answers are grounded in this paper and cite their sources.
Should not yet change postdilation practice in STEMI PCI; leaves open need for RCTs to confirm DOCE benefit.
AIM: Achieving the optimal apposition of coronary stents during percutaneous coronary intervention is not always feasible. The risks and benefits of stent postdilation in primary percutaneous coronary intervention (PPCI) in patients with ST-elevation myocardial infarction (STEMI) have remained controversial. We sought to evaluate the immediate angiographic and long-term outcomes in patients with and without stent postdilation. METHODS: A cohort of patients (n = 1,224) with STEMI, treated with PPCI (n = 500 postdilated; n = 724 controls), were studied. The flow grade, the myocardial blush grade, and the frame count were considered angiographic outcomes. The clinical outcomes were major adverse cardiovascular events (MACE)-comprising cardiac death, nonfatal MI, and repeat revascularization-and the device-oriented composite endpoint (DOCE)-consisting of cardiac death, target lesion revascularization, and target vessel revascularization. RESULTS: The flow and myocardial blush grades were not different between the two groups, and the frame count was significantly lower in the postdilation group (15.7 ± 8.4 vs. 17 ± 10.4; p < .05). The patients were followed up for 348 ± 399 days. DOCE (2.2% vs. 5.8%) and cardiac mortality (1.2% vs. 3.2%) were lower in the postdilation group. In the fully adjusted propensity score-matched analysis, postdilation was associated with decreased DOCE (HR = 0.40 [0.18-0.87], p = .021). CONCLUSIONS: Selective postdilation improved some angiographic and clinical outcomes and could not be discouraged in PPCI on patients with STEMI.
No takes yet. Share an insight, caveat, or question.
Saadat et al. (2019) conducted a cohort in ST-elevation myocardial infarction (STEMI) (n=1,224). Stent postdilation vs. No stent postdilation was evaluated on Device-oriented composite endpoint (DOCE) (HR 0.40, 95% CI 0.18-0.87, p=0.021). Stent postdilation during primary percutaneous coronary intervention for STEMI was associated with a decreased risk of the device-oriented composite endpoint.
Synapse has enriched 10 related papers. Consider them for comparative context: